Pipeline Analysis

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1085982

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1085982

Polycythemia Vera Therapeutics Market, by Disease Type, by Drug Class, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

PUBLISHED: May 5, 2022

PAGES: 218 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Polycythemia vera is a blood disorder in which the body creates too many red blood cells. These extra red cells make blood thicker than normal. The thickened blood flows slower and may clot within body. Red blood cells carry oxygen to organs and tissues throughout the body. If the blood moves too slowly or clots, the cells cannot deliver enough oxygen. This situation can cause serious complications including heart attack, stroke, and heart failure. There are two types of polycythemia vera, which include primary polycythemia vera and secondary polycythemia vera. Polycythemia vera gets worse with time if remain undiagnosed and can be life-threatening. Polycythemia vera can be treatable but is not curable. Polycythemia vera treatment may include phlebotomy and drug therapy. Phlebotomy involves the removal of blood from the body. Drug therapy involves the use of Hydroxyurea and Interferon-alfa. Patients who do not respond to hydroxyurea are treated with ruxolitinib (jakafi) or busulfan. At times a low dose of aspirin, allopurinol and antihistamines are also preferred for polycythemia vera treatment. Givinostat is an emerging drug in global polycythemia vera treatment market.

Market Dynamics

The increasing incidence of polycythemia vera, rising research and development activities for the development of novel therapeutics for the treatment of polycythemia vera, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global polycythemia vera therapeutics market over the forecast period.

For instance, according to the National Organization for Rare Disorders, polycythemia vera affects slightly more men than women and the disorder is estimated to affect around 44 to 57 per 100,000 people in the U.S. each year It occurs most often in individuals over 60 years old, but can affect individuals of any age. It is extremely rare in individuals under the age of 20.

Key features of the study:

This report provides in-depth analysis of the global polycythemia vera therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global polycythemia vera therapeutics market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Pfizer Inc, Galena Biopharma, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, PharmaEssentia Corporation, Bayer AG, Mylan N.V., Teva Pharmaceuticals Industries Ltd, GlaxosmithKline plc, ANP Technologies, INC., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc, Karus Therapeutics Limited, and Miragen Therapeutics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global polycythemia vera therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global polycythemia vera therapeutics market

Detailed Segmentation:

Global Polycythemia Vera Therapeutics Market, By Disease Type:
- Primary Polycythemia Vera
- Secondary Polycythemia Vera
Global Polycythemia Vera Therapeutics Market, By Drug Class:
- Antimetabolite
- Kinase Inhibitors
- Alpha Interferon
- Selective Serotonin Reuptake Inhibitors
- Others
Global Polycythemia Vera Therapeutics Market, By Route of Administration:
- Oral
- Intravenous
- Intramuscular
- Subcutaneous
Global Polycythemia Vera Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Polycythemia Vera Therapeutics Market, By Region:
- North America
  - By Disease Type
  - Primary Polycythemia Vera
  - Secondary Polycythemia Vera
  - By Drug Class
  - Antimetabolite
  - Kinase Inhibitors
  - Alpha Interferon
  - Selective Serotonin Reuptake Inhibitors
  - Others
  - By Route of Administration
  - Oral
  - Intravenous
  - Intramuscular
  - Subcutaneous
  - By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country
  - U.S.
  - Canada
- Latin America
  - By Disease Type
  - Primary Polycythemia Vera
  - Secondary Polycythemia Vera
  - By Drug Class
  - Antimetabolite
  - Kinase Inhibitors
  - Alpha Interferon
  - Selective Serotonin Reuptake Inhibitors
  - Others
  - By Route of Administration
  - Oral
  - Intravenous
  - Intramuscular
  - Subcutaneous
  - By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - By Disease Type
  - Primary Polycythemia Vera
  - Secondary Polycythemia Vera
  - By Drug Class
  - Antimetabolite
  - Kinase Inhibitors
  - Alpha Interferon
  - Selective Serotonin Reuptake Inhibitors
  - Others
  - By Route of Administration
  - Oral
  - Intravenous
  - Intramuscular
  - Subcutaneous
  - By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - By Disease Type
  - Primary Polycythemia Vera
  - Secondary Polycythemia Vera
  - By Drug Class
  - Antimetabolite
  - Kinase Inhibitors
  - Alpha Interferon
  - Selective Serotonin Reuptake Inhibitors
  - Others
  - By Route of Administration
  - Oral
  - Intravenous
  - Intramuscular
  - Subcutaneous
  - By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - By Disease Type
  - Primary Polycythemia Vera
  - Secondary Polycythemia Vera
  - By Drug Class
  - Antimetabolite
  - Kinase Inhibitors
  - Alpha Interferon
  - Selective Serotonin Reuptake Inhibitors
  - Others
  - By Route of Administration
  - Oral
  - Intravenous
  - Intramuscular
  - Subcutaneous
  - By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - By Disease Type
  - Primary Polycythemia Vera
  - Secondary Polycythemia Vera
  - By Drug Class
  - Antimetabolite
  - Kinase Inhibitors
  - Alpha Interferon
  - Selective Serotonin Reuptake Inhibitors
  - Others
  - By Route of Administration
  - Oral
  - Intravenous
  - Intramuscular
  - Subcutaneous
  - By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country/Region
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
- Pfizer Inc *
  - Company Overview
  - Material Portfolio
  - Financial Performance
  - Key Highlights
  - Market Strategies
- Galena Biopharma
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly and Company
- PharmaEssentia Corporation
- Bayer AG
- Mylan N.V.
- Teva Pharmaceuticals Industries Ltd
- GlaxosmithKline plc
- ANP Technologies, INC.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc
- Karus Therapeutics Limited
- Miragen Therapeutics, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI4540

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Disease Type
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Pipeline Analysis
PEST Analysis
Regulatory Scenario
Market Trends
Key Highlights
Reimbursement Scenario
Mergers & Acquisitions

4. Global Polycythemia Vera Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic

Economic Impact
Impact on Clinical Trials and Drug Development
Government Initiatives

5. Global Polycythemia Vera Therapeutics Market, By Disease Type, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Primary Polycythemia Vera
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Secondary Polycythemia Vera
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global Polycythemia Vera Therapeutics Market, By Drug Class, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Antimetabolite
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Kinase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Alpha Interferon
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Selective Serotonin Reuptake Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global Polycythemia Vera Therapeutics Market, By Route of Administration, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Intramascular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

8. Global Polycythemia Vera Therapeutics Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

9. Global Polycythemia Vera Therapeutics Market, By Region, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
North America
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- U.S.
- Canada
Latin America
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
Africa
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Region/Country, 2017 - 2028, (US$ Mn)
- South Africa
- Central Africa
- North Africa

10. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Galena Biopharma
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- PharmaEssentia Corporation
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Mylan N.V.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Teva Pharmaceuticals Industries Ltd
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxosmithKline plc
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- ANP Technologies, INC.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Gilead Sciences, Inc
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Karus Therapeutics Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Miragen Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Analyst Views

11. Section

References
Research Methodology
About us and Sales Contact

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ